Revolutionising cancer diagnostics
A step change in the detection, diagnosis and monitoring of disease.
Biofidelity’s unique ASPYRE technology enables fast, simple and ultra-sensitive detection of genetic panels from both tissue and liquid biopsies using existing laboratory instrumentation.
ASPYRE-Lung
Comprehensive coverage of NCCN guideline recommended markers for NSCLC
- 111 markers across 11 genes
- 0.1% allele-fraction sensitivity in a simple workflow
- Simultaneous DNA & RNA analysis on one instrument
Latest News
Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology
01 February 2022
01 February 2022
Biofidelity Adds Lee N. Newcomer, MD to Scientific Advisory Board Ahead of ASPYRE Launch
06 January 2022
06 January 2022
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients
13 October 2021
13 October 2021
Successful alpha testing of Biofidelity’s ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use
14 September 2021
14 September 2021